A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function
PHASE1CompletedINTERVENTIONAL
Enrollment
16
Participants
Timeline
Start Date
January 30, 2023
Primary Completion Date
April 4, 2023
Study Completion Date
April 4, 2023
Conditions
Hepatic Impairment
Interventions
DRUG
Apraglutide
Single dose of apraglutide
Trial Locations (2)
Unknown
APEX, Münich
Summit Clinical Research, Bratislava
All Listed Sponsors
lead
VectivBio AG
INDUSTRY
NCT05706623 - A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function | Biotech Hunter | Biotech Hunter